Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
27(71%)
Results Posted
0%(0 trials)
Terminated
1(3%)

Phase Distribution

Ph early_phase_1
1
3%
Ph phase_2
23
61%
Ph phase_3
2
5%
Ph phase_1
11
29%

Phase Distribution

12

Early Stage

23

Mid Stage

2

Late Stage

Phase Distribution37 total trials
Early Phase 1First-in-human
1(2.7%)
Phase 1Safety & dosage
11(29.7%)
Phase 2Efficacy & side effects
23(62.2%)
Phase 3Large-scale testing
2(5.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

20.0%

1 of 5 finished

Non-Completion Rate

80.0%

4 ended early

Currently Active

27

trials recruiting

Total Trials

38

all time

Status Distribution
Active(30)
Completed(1)
Terminated(4)
Other(3)

Detailed Status

Recruiting17
Active, not recruiting10
Withdrawn3
Not yet recruiting3
Suspended2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
38
Active
27
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (2.7%)
Phase 111 (29.7%)
Phase 223 (62.2%)
Phase 32 (5.4%)

Trials by Status

recruiting1745%
active_not_recruiting1026%
suspended25%
unknown13%
completed13%
withdrawn38%
not_yet_recruiting38%
terminated13%

Recent Activity

Clinical Trials (38)

Showing 20 of 38 trialsScroll for more
NCT05572970

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

Unknown
NCT07551596Phase 2

Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial

Not Yet Recruiting
NCT06843434Phase 2

A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma

Recruiting
NCT05363709Phase 2

BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients

Active Not Recruiting
NCT07152821Phase 3

Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma

Recruiting
NCT06346197Phase 3

Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

Recruiting
NCT04028063Phase 2

Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

Active Not Recruiting
NCT07516366Phase 2

Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial

Not Yet Recruiting
NCT07128355Early Phase 1

Botensilimab, Balstilimab, and SBRT in Colorectal Cancer

Not Yet Recruiting
NCT06300463Phase 2

Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases

Recruiting
NCT03860272Phase 1

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Active Not Recruiting
NCT06336902Phase 1

Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer

Recruiting
NCT04943848Phase 1

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

Recruiting
NCT05845450Phase 2

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

Recruiting
NCT06279130Phase 2

Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations

Recruiting
NCT05928806Phase 2

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

Suspended
NCT07227636Phase 2

A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy

Recruiting
NCT06268015Phase 2

Botensilimab and Balstilimab Optimization in Colorectal Cancer

Active Not Recruiting
NCT05672316Phase 1

Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy

Active Not Recruiting
NCT05529316Phase 2

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Active Not Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
38